A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

NCT07382739 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Phase 2
Radiotherapy-Induced Immune Priming
Elranatamab
Relapsed Refractory Multiple Myeloma (RRMM)
Extramedullary Disease in Multiple Myeloma
Paramedullary Disease
PMD

Interventions

DRUG: Elranatamab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]